

June 12 , 2012

Tokyo, Japan

Micron, Inc.

## **PRESS RELEASE**

### **Collaboration agreement between Micron, Inc. and CNPK for the joint development of imaging clinical trial network in China**

Micron Inc. (Henceforth "Micron", Headquarters: Kobe, Japan) and CNPK (Beijing, China), which belongs to China Nucleon Medical Technology Group ( Hongkong, China) have entered into a collaboration agreement regarding international collaborative imaging trials.

Recent years in drug development have seen the wide use and increasing importance of imaging technology to accurately evaluate drug efficacy and safety in shorter period of time, compared to conventional clinical trials. In particular, this trend is clearly evident in malignant tumor and central nervous system disease studies. A great number of clinical trials use imaging technology as primary endpoints to conduct appropriate data collection and analysis.

Currently, many international collaborative clinical trials are being conducted in Asia, thus there are demands for the collection and analysis of high quality international-level clinical data. Therefore, imaging technology is becoming more popular. For that reason, we have created an imaging clinical trial network in Asia to meet the needs of companies from around the world. Since CNPK offers clinical trial support for drug development in China, which is one of the key locations in Asia, we have entered into a collaboration agreement for the purpose of constructing a network for international imaging clinical trial collaboration.

As an imaging CRO, Micron is supporting the efficient drug development with PET, MRI, CT and other imaging applications in the fields of Oncology and CNS. We are planning to utilize the CNPK's clinical network, expertise in PET tracer synthesis, standardization of imaging, quality check, and imaging analysis, as well CNPK's animal laboratory for preclinical platform.

CNPK is a pioneer in Molecular Imaging CRO for pharmaceutical industry in China. CNPK is committed to offering functional images in the evaluation of pharmacodynamics and pharmacokinetics of new drug and molecular probe development, a novel time-saving approach to support new drug invention. The services for clinical trials provided by CNPK include pre-clinical new drug development service, molecular imaging site management service on multi-center clinical trials, radioactive probe compounding and conventional CRO service. And for pre-clinical trials, CNPK's research laboratory was founded in Wuxi in 2010 and has since established good progress in assisting various customers in their drug discovery endeavors and CNPK is currently working on establishing two more research facilities in other major cities to serve the growing needs of the industry.

CNPK's biggest strengths are clinical trial network throughout China and pre-clinical platform in Molecular Imaging. Two thirds of PET-CT centers/hospitals (120 of 180) in China are CNPK's partners or clients, and half of them are GCP certified by SFDA.

CNPK views the joint-work with MICRON as an international collaboration to attract clients for efficient and effective pre-clinical and clinical studies in molecular imaging with high quality standard. CNPK is 100% wholly owned subsidiary of CNMT, and CNPK is acquired with 1st level support from CNMT when utilizing clinical resource among the national PET tracer distribution network.

In addition, CNPK is a wholly owned subsidiary under CNMT group that has focused last decade on providing needed solutions to nuclear medicine community in China, such as marketing advanced cyclotron equipment, building up radio-pharmaceutical distribution network with current coverage over 130 hospital customers across 20 provinces. CNPK is acquired with 1st level support from CNMT when utilizing clinical resource among the national PET tracer distribution network.

## **Outline of each company**

Micron, Inc.

Established: October, 2005

Headquarters: Kobe, Japan

President and CEO: Makoto Sato

Main Services: Imaging related technical support and clinical trial support.

China Nucleon Medical Technology Group

Established: October, 2009

Headquarters: Hongkong, China

Chairman: Chih Chen

Main Services: marketing advanced cyclotron equipment, building up radio-pharmaceutical distribution network, developing novel tracers, providing imaging and conventional CRO services (including pre-clinical new drug development service, site management service on multi-center clinical trials).

## **Contact information for inquiries**

Micron, Inc.

Contacts: Michita Sato, Business Development Division (for companies in Japan)

Michael Tintiuc, Director of Foreign Affairs (for companies outside of Japan)

TEL: +81-3-6268-0305

E-mail: [info@micron-kobe.com](mailto:info@micron-kobe.com)

Company Website: <http://www.micron-kobe.com>